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Chapter 1 
INTRODUCTION 
1.1 CANCER: 
Cancer is the uncontrolled growth of abnormal cells, forming malignant tumors, and 
invading other parts of the body. Normal cells have constant signals that dictate whether cells 
should divide and differentiate into another cell or die. Cancer cells develop a degree of anatomy 
from the signals, resulting in uncontrolled growth and proliferation. If this unregulated 
proliferation is allowed to continue, it could be fatal. 
Cancer remains the second leading cause of death in the United States and the leading 
cause of death among the most productive age group, i.e., those aged 45–64 y [1].The causes of 
cancer are diverse and complex. There are many factors that increase the risk of cancer, which 
are exposure to radiation, environmental pollutants, certain infections, tobacco use, 
certain dietary factors, obesity and lack of physical activity 
[2]
. These factors directly damage 
genes or combine with existing genetic errors within the cells to cause mutations
 [3]
. 
Tumorigenesis in humans is a multistep process, where normal cells get transformed into 
malignant cancer cells 
[4]
. Cancer progression or tumorigenesis involves the following steps 
[5]
: 
Initiation- Initiation is occurrence of mutation on a chromosome, or in a gene segment of DNA. 
Usually, initiation is not enough to produce cancer as the body’s repair systems can replace 
damaged sections of DNA. If the cell reproduces with that damaged DNA then more abnormal 
cells can be made that may develop into cancer. 
Promotion- The altered cells undergo more changes that may require a promoter. A promoter is 
the one that speeds up the pace of cell division and creates more genetic mutations. A promoter 
can be a hormone like estrogen or any toxic substance like a chemical in tobacco smoke. 
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Progression- The cells that begin to grow out of control form the basis for all cancers. These out 
of control cells form tumor. The progression of cancer depends upon the body conditions such as 
genetic factors and hormones. 
Metastasis is the process by which cancer cells spread to other parts of the body and the 
cancer is called the metastatic cancer 
[6][7]
. Metastatic cancer will have the same name and the 
same type of cancer cells as the original. Usually cancer is treated by chemotherapy, radiation 
therapy and surgery but there are also other cancer therapies like immunotherapy, targeted 
therapy, hyperthermia, stem cell transplant and use of lasers. 
1.2 LUNG CANCER: 
The leading cause of cancer deaths in the United States is lung cancer, and the most 
common type of cancer diagnosed in men 
[8]
.  The primary function of the lungs is to exchange 
gases. Carbon dioxide is removed from the bloodstream and oxygen enters the bloodstream from 
the air we breathe. This is performed by the lung. The right lung has three lobes, whereas the left 
lung has two lobes and a small structure called the lingula. It corresponds to the middle lobe of 
the right lung. Bronchi are the major airways that enter the lungs and arise from the trachea. The 
bronchi branch into bronchioles which are smaller airways. Bronchioles end in tiny sacs known 
as alveoli where the gas exchange takes place 
[9]
.  
Most cancers that start in lung are carcinomas that are derived from epithelial cells. Lung 
cancer spreads or metastasizes in very early stages after it forms 
[9]
. It is a very life-threatening 
cancer and one of the most difficult cancers to treat because it tends to spread in this way even 
before it can be detected on an imaging test such as a chest x-ray 
[10]
. The most common sites for 
metastasis of lung cancer are the adrenal glands, brain, bones and liver. But lung cancer can also 
spread to other parts of the body 
[9]
.   
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1.2.1 Causes of Lung Cancer: 
a) Smoking 
The most common cause of lung cancer is long-term exposure to tobacco smoke, which 
causes 80–90% of lung cancers [11]. Nonsmokers account for 10–15% of the cases[12], and these 
cases are often ascribed to a combination of genetic factors, air pollution, radon gas, asbestos 
and second-hand smoke
[13][14][15][16]
. Tobacco smoke contains more than 4,000 chemical 
compounds which are cancer-causing or carcinogenic. Nitrosamines and polycyclic aromatic 
hydrocarbons are two primary carcinogens present in tobacco smoke. Following smoking 
cessation new normal cells grow and replace the damaged cells in the lung. This decreases the 
risk of developing lung cancer each year. In former smokers, the risk of developing lung cancer 
begins to approach that of a nonsmoker about 15 years after cessation of smoking 
[9]
. 
b) Passive smoking 
Passive smoking is another risk factor for lung cancer development. Research has shown 
that there is a 24% increase in risk for developing lung cancer for nonsmokers who reside with a 
smoker when compared with nonsmokers who do not reside with a smoker 
[9]
. The risk appears 
to increase with increase in degree of exposure. 3,000 lung cancer deaths that occur every year in 
U.S. are attributed to passive smoking 
[9]
. 
c) Asbestos Fibers 
Mesothelioma is a cancer of the pleura of the lung. It is also cancer of the lining of the 
abdominal cavity called the peritoneum. Both lung cancer and Mesothelioma have exposure to 
asbestos as an established risk factor. Asbestos-related lung cancer in workers exposed to 
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asbestos is drastically increased by cigarette smoking. A fivefold greater risk of developing lung 
cancer is associated with asbestos workers who do not smoke than nonsmokers, but asbestos 
workers who smoke have a risk that is fifty- to ninety-fold greater than nonsmokers. 
d) Radon gas 
Radon gas is a known cause of lung cancer. An estimated 12% of lung-cancer deaths are 
attributed to radon gas or about 20,000 lung-cancer-related deaths annually in the U.S. This 
makes radon gas the second leading cause of lung cancer in the U.S. Radon gas is a natural 
radioactive gas formed as a natural decay product of Uranium. As with asbestos exposure, radon 
exposure coordinated with smoking greatly increases the risk of lung cancer.  
e) Familial Predisposition 
Majority of lung cancers are associated with tobacco smoking, but not all smokers 
eventually develop lung cancer. This suggests that other factors may play a role in the causation 
of lung cancer such as individual genetic susceptibility. Numerous studies showed that lung 
cancer is more likely to occur in both smoking and non-smoking relatives of those who have had 
lung cancer compared to the general population. Recent research has localized a region on the 
long (q) arm of the human chromosome number 6 that is likely to contain a gene that confers an 
increased susceptibility to the development of lung cancer in smokers. 
f) Air pollution 
Air pollution is another important cause of lung cancer. Pollution from vehicles, industry, 
and power plants, can increase the likelihood of developing lung cancer in individuals exposed to 
it. Up to 1% of lung cancer deaths are attributable to breathing polluted air, and experts believe 
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that prolonged exposure to highly polluted air can carry a risk similar to that of passive smoking 
for the development of lung cancer. 
g) Prior history of lung cancer 
Previous survivors of lung cancer have a greater risk compared to the general population 
of developing a second lung cancer. An additional risk for of 1-2% per year exists to develop a 
second lung cancer in survivors of non-small cell lung cancers (NSCLCs).  6% per year is the 
risk for development of second cancers in survivors of small cell lung cancers (SCLCs). 
1.2.2 Symptoms: 
According to American Cancer Society and Cancer Research UK, symptoms are not seen 
in most of the lung cancers until they have spread to other parts of the body. Some people show 
symptoms in early stages. Some common symptoms of lung cancer are cough, chest pain, 
hoarseness, loss of weight and appetite, coughing up blood or rust-colored sputum (spit or 
phlegm), shortness of breath, feeling tired or weak, infections such as bronchitis and pneumonia 
that don’t go away or keep coming back, new onset of wheezing. 
If it spreads to distant organs, the most likely symptoms are bone pain, headache, 
weakness or numbness of arms and legs, dizziness, balance problems, or seizures caused by 
cancer spread to the brain or spinal cord, yellowing of the skin and eyes caused by cancer spread 
to the liver. Hoarse voice, difficulty in swallowing, finger clubbing, swelling of the face caused 
by a blockage of a main blood vessel, swelling in the neck caused by enlarged lymph nodes, pain 
or discomfort under your ribs on your right side are some less common symptoms of lung 
cancer. 
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1.2.3 Lung Cancer Staging: 
Staging is essential in the proper selection of treatment for individual patients. The 
American Joint Committee for Cancer Staging has recommended staging of lung cancer which is 
more precise definition of the extent of the disease. This classification covers the size and 
location of the tumor, the extent of the metastases to the lymph nodes, and the presence and 
extent of distant metastases. TO to T4 classification defines the size and location of primary 
tumors, NO to N2 classification defines the extent of nodal metastases and whether distant 
metastases are present.  To evaluate the results of therapy and for defining appropriate therapy 
for the individual patient there is another classification.  
T system shows about primary tumors:  
T0 
 
 
 
TX 
 
 
 
 
 
 
 
 
 
 
T1 
 
 
 
 
 
 
No evidence of primary tumor 
 
Tumor proven by presence of malignant cells 
in bronchopulmonary secretions but           
not visualized roentgenographically or 
bronchoscopically 
 
Tumor that is 3.0 cm or less in greatest 
diameter, surrounded by lung or visceral 
pleura, and without evidence of invasion 
proximal to lobar bronchus at bronchoscopic 
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Table 1:  T system of Lung Cancer Staging: Peters, R. M. "Staging of lung cancer." CHEST Journal 71.5 
(1977): 633-634 
 
 
 
 
 
 
T2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T3 
examination 
 
Tumor more than 3.0 cm in diameter or 
tumor of any size which, with its associated 
atelectasis or obstructive pneumonitis, 
extends to hilar region. (at bronchoscopic 
examination, proximal extent of 
demonstrable tumor must be at least 2.0 cm 
distal to earina; any associated atelectasis or 
obstructive pneumonitis must involve less 
than an entire lung, and there must be no 
pleural effusion) 
 
Tumor of any size with direct extension into 
adjacent structure (such as chest wall, 
diaphragm, or mediastinum and its contents) 
or demonstrable bronchoscopically to be less 
than 2.0 cm distal to carina, or any tumor 
associated with atelectasis or obstructive 
pneumonitis of entire lung or pleural effusion 
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N system shows about regional lymph nodes:  
NO 
 
 
N1 
 
 
N2 
demonstrable metastasis to regional lymph 
nodes 
 
Metastasis to lymph nodes in ipsilateral hilar 
region (including direct extension) 
 
Metastasis to lymph nodes in mediastinum 
 
Table 2: N system of Lung Cancer Staging: Peters, R. M. "Staging of lung cancer." CHEST Journal 71.5 
(1977): 633-634 
 
M system shows distant metastases:  
M0 
 
M1 
No distant metastasis 
 
Distant metastasis, such as In scalene, 
cervical, or contralateral hilar lymph nodes, 
brain, bones, lung, liver, etc. 
Table 3: M system of Lung Cancer Staging: Peters, R. M. "Staging of lung cancer." CHEST Journal 71.5 
(1977): 633-634 
Stage grouping TNM subsets: 
Stage TNM subset 
Occult carcinoma  Occult carcinoma with bronchopulmonary 
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TXNO MO 
 
 
 
 
Invasive carcinoma, stage 1  
T1 NO MO  
T1 N1 MO  
T2 NO MO 
 
 
 
 
 
 
Stage 2  
T2 N1 MO 
 
Stage 3 
T3 with any N or M 
N2 with any T or M 
M1 with any T or N  
secretions containing malignant cells but 
without other evidence of primary tumor or 
evidence of metastasis to regional lymph 
nodes or distant metastasis 
 
Tumor that can be classified T1 without any 
metastasis or with metastasis to lymph nodes 
in ipsilateral hilar region only, or tumor that 
can be classified T2 without any metastasis to 
nodes or distant metastasis (note that TX N1 
MO and TO N1 MO are also theoretically 
possible, but such a clinical diagnosis would 
be difficult, if not impossible, to make; if 
such a diagnosis is made, it should be 
included in stage 1) 
 
Tumor classified as T2 with metastasis to 
lymph nodes in ipsilateral hilar region only 
 
Any tumor more extensive than N2 with any 
T or M T2 or any tumor with metastasis Mi 
with any T or N to lymph nodes in 
mediastinum or with distant metastasis 
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Table 4: TNM stage grouping: Peters, R. M. "Staging of lung cancer." CHEST Journal 71.5 (1977): 633-634 
1.2.4 Types of Lung Cancer: 
The main types of lung cancer are small-cell lung carcinoma (SCLC) which is also called 
oat cell cancer that accounts for about 15% of all lung cancer cases. They are the most aggressive 
and rapidly growing. They metastasize to many sites in the body and are located after they have 
spread. Non-small-cell lung carcinoma (NSCLC) that accounts for about 80% of all lung cancer 
cases, with less than 15% of patients surviving beyond 5 years
[17][18]
. The major types of NSCLC 
are adenocarcinoma, squamous cell carcinoma and large cell carcinoma, but there are also 
several other types which occur less frequently 
[19]
. Adenocarcinoma is a 
cancer of epithelial tissue which has glandular origin, glandular characteristics, or both. It is the 
most common form of lung cancer in people 
[20]
. Nearly 40% of all lung cancers in the US are 
adenocarcinoma that originates in peripheral lung tissue 
[21]
. Inhalation of cigarette smoke results 
in peripheral lesions which are mostly the case in adenocarcinomas of the lung. Generally, they 
grow more slowly and form smaller masses than the other subtypes 
[22]
. However, they tend to 
form metastases widely at an early stage. A549 and H1299 are two cell lines of adenocarcinoma 
that have been used in this study.  
A549 Cell line: 
The A549 cell line was first developed in 1972 b D.J Giard, et al. through the removal 
and culturing of cancerous lung tissue in the explanted tumor of 58-year-old caucausian male 
[23]
. 
This type of cell, in a normal lung, is squamous and performs the task of diffusing water, 
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electrolytes and other substances across the surface of the alveoli. They grow adherently, as a 
monolayer, in vivo 
[24]
. 
H1299 Cell line: 
H1299 was initially established from the lung cells of a 43-year-old Caucasian male 
patient who suffered from non-small cell lung cancer 
[25]
. These cells were derived from the 
lymph node metastatic site, and exhibit epithelial cell morphology 
[26]
. They lack expression of 
the p53 protein 
[27]
. 
1.2.5 Diagnosis and Treatment: 
Physical examinations and symptoms may show cancer development. Difficulty in 
breathing, obstruction in airway, or lung infections may also be counted as signs. There are some 
signs by which chronic lung disease can be indicated. They are cyanosis which is indicated by 
bluish color of the skin and the mucous membranes caused due to insufficient oxygen in the 
blood and also clubbing which is associated with changes in the tissue of the nail beds 
[9]
. There 
are some common techniques that are followed to diagnose lung cancer. 
Chest X-ray is the first diagnostic step and the most common way to detect lung cancer. 
It involves back to front view of the chest also a view from the side. Chest X-ray reveals 
suspicious areas in the lungs that are abnormal but cannot determine if the areas are cancerous. 
Particularly, benign tumors or calcified nodules in the lungs called as hamartomas may be 
identified on a chest X-ray which mimics lung cancer. 
CT (computerized tomography) scan is performed to evaluate both metastatic and non-
metastatic lung cancer. It is performed on the chest, abdomen, and/or brain. A CT scan is 
performed particularly of chest, when an X-ray does not show sufficient information about the 
12 
 
 
location or extent of cancer. CT scans are same as X-ray procedures that combine multiple 
images with the help of a computer and generate cross-sectional views of the body. In a CT scan 
the patient is exposed to a minimal amount of radiation. The most common side effect of CT 
scan may result in itching as a result of an adverse reaction to intravenous contrast material that 
may have been given prior to the procedure. But that disappears quickly. Severe reactions are 
rare. CT scans in different parts of the body reveal the locations of metastasis like a scan of 
abdomen identifies metastasis in the liver or adrenal glands. A CT scan of the head reveals the 
presence and extent of metastatic cancer in the brain. 
Normally, to increase resolution helical CT scan (spiral CT scan) is performed which 
involves movement in a spiral pattern. This is recommended in low-dose for smokers of ages 
between 55 and 80 who have at least a 30 year history of smoking. This increases the chances of 
detecting smaller lung cancers which are more curable.  
Magnetic resonance imaging (MRI) scans use magnetism, radio waves, and a computer to 
produce images. These are used when precise detail about a tumor location is needed. The 
procedure is similar to CT scanning where the patient is placed on a moveable bed which is 
inserted into the MRI scanner. There is no chance of exposure to radiation in MRI scanning and 
no known side effects. The image and resolution built by MRI is in such detail that it can detect 
tiny changes in structures within the body. MRI cannot be used for patients with medical devices 
like pace maker because of the risk of the magnet moving the metal parts of these structures. 
Positron emission tomography (PET) scanning is a specialized imaging technique which 
produces three-dimensional colored images of the substances in the tissues within the body. This 
technique uses radioactive drugs.  While CT scans and MRI scans look at anatomical structures, 
PET scans measure metabolic activity and the function of tissues. PET scans determine if a 
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tumor tissue is growing actively and aids in ascertaining the type of cells within a particular 
tumor. In PET scanning, the patient receives a short half-lived radioactive drug, receiving 
approximately twice amount of radiation exposure as chest X-rays. The drug accumulates in 
certain tissues more than in others depending on the drug. The drug releases particles known as 
positrons from tissues that take them up. As the positrons encounter electrons in the body, a 
reaction takes place releasing gamma rays. A scanner records these gamma rays and maps the 
area where the radioactive drug has accumulated.  
Therapies for lung cancer can be curative (removal or eradication of a cancer) or 
palliative (measures that are unable to cure a cancer but can reduce pain and suffering). 
Sometimes more than one type of therapy is prescribed. In such cases, the second therapy is 
referred to as adjuvant therapy. Chemotherapy or radiotherapy is an example of adjuvant 
therapy, after surgical removal. 
Surgery for removal of the tumor is generally performed at earlier stages (stage I or 
sometimes stage II) of cancer. It is the treatment of choice for cancer that has not spread beyond 
the lung. About 10%-35% of lung cancers can be removed surgically, but removal does not 
always result in a cure, since the tumors may already have spread and can recur at a later time. 
Surgery is less often performed with SCLC than with NSCLC because these tumors are less 
likely to be localized to one area that can be removed. The procedure chosen depends on the size 
and location of the tumor. Surgeons must open the chest wall and may perform a wedge 
resection of the lung (removal of a portion of one lobe), a lobectomy (removal of one lobe), or a 
pneumonectomy (removal of an entire lung), lymphadenectomy (removal of lymphnodes). After 
the surgical procedure, patients may experience difficulty in breathing, pain and weakness. The 
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risks of surgery include complications due to bleeding, infection, and complications of general 
anesthesia. 
Radiation therapy (RT) is an essential part of lung cancer management 
[28]
. In the past 
decade, significant improvements have been made in radiation treatment, available to advances 
in biology, physics and clinical research 
[23]
.  Radiation therapy can be used for both NSCLC and 
SCLC. It uses high-energy X-rays or other types of radiation to kill dividing cancer cells. It can 
be given as curative therapy, palliative therapy (using lower doses of radiation than with curative 
therapy), or as adjuvant therapy in combination with surgery or chemotherapy. It can be either 
external by using a machine that delivers radiation, or internal through radioactive substances in 
sealed containers administered in to the area where the tumor is localized. Radiation therapy is 
used if surgical removal is impossible due to the spreading of tumor to areas such as the lymph 
nodes or trachea. Radiation therapy generally shrinks a tumor or limits its growth when given as 
a sole therapy, yet in 10%-15% of people it leads to long-term remission and palliation of the 
cancer. Combining radiation therapy with chemotherapy can further prolong survival when 
chemotherapy is administered. Radiation therapy does not carry the risks of major surgery, but 
side effects include fatigue and lack of energy. A reduced white blood cell count and low blood 
platelet levels (leading to excessive bleeding) also can occur with radiation therapy. If the 
digestive organs are exposed to radiation, patients may experience nausea, vomiting, or diarrhea. 
Radiation therapy can irritate the skin in the area that is treated, but this irritation generally 
improves with time after treatment has ended. 
Chemotherapy is also given to both NSCLC and SCLC. Chemotherapy is the process of 
administrating drugs that stop the growth of cancer cells by killing them or preventing them from 
dividing. Chemotherapy can be given alone or as an adjuvant to surgical therapy, or in 
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combination with radiotherapy. A class of drugs known as the platinum-based drugs has been the 
most effective in treatment of lung cancers through chemotherapy. 
Chemotherapy is the treatment of choice for most SCLC, since these tumors are generally 
widespread in the body when they are diagnosed. Chemotherapy alone is not particularly 
effective in treating NSCLC, but when NSCLC has metastasized it can prolong survival in many 
cases. Chemotherapy may be given as pills, as an intravenous infusion, or as a combination of 
the two. A combination of drugs is given in a series of treatments, called cycles, over a period of 
weeks to months, with breaks in between cycles. Unfortunately, the drugs used in chemotherapy 
also kill normally dividing cells in the body, resulting in unpleasant side effects. Damage to 
blood cells can result in increased susceptibility to infections and difficulties with blood clotting 
(bleeding or bruising easily). Other side effects include fatigue, weight loss, hair loss, nausea, 
vomiting, diarrhea, and mouth sores. The side effects of chemotherapy vary according to the 
dosage and combination of drugs used and may also vary from individual to individual. 
Medications have been developed that can treat or prevent many of the side effects of 
chemotherapy. The side effects generally disappear during the recovery phase of the treatment or 
after its completion. 
Molecular targeted therapy involves the administration of drugs which target tumors with 
specific genetic changes. For example, the drugs erlotinib (Tarceva) and gefitinib (Iressa) are so-
called targeted drugs, which may be used in certain patients with NSCLC who are no longer 
responding to chemotherapy. Targeted therapy drugs more specifically target cancer cells, 
resulting in less damage to normal cells than general chemotherapeutic agents. Erlotinib and 
gefitinib target a protein called the epidermal growth factor receptor (EGFR) that is important in 
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promoting the division of cells. This protein is found at abnormally high levels on the surface of 
some types of cancer cells, including many cases of non-small cell lung cancer. 
Other examples of targeted therapy include antiangiogenesis drugs that block the 
formation of new blood vessels within the cancer which leads to deficiency in oxygen-carrying 
blood and the cancer cells die. Cetuximab is an antibody that binds to the epidermal growth 
factor receptor (EGFR). In patients with NSCLC whose tumors have been shown to express the 
EGFR by immunohistochemical analysis, the addition of cetuximab may be considered for some 
patients. Other targeted therapies include ALK tyrosine kinase inhibitor drugs (for example, 
crizotinib, ceritinib) that are used in patients whose tumors have an abnormality of the ALK 
gene. 
Despite these improvements in the therapeutic regimes, local recurrence of lung cancer 
remains a relentless problem 
[24]
. Thus, it is necessary to develop more effective approaches for 
the treatment of NSCLC.  
1.3 Nutrition and Cancer: 
Research in 1990’s has recognized that certain nutrients have potent biological effects in 
addition to their nutritional value 
[29]
. Diet has a major influence in cancer prevention. The World 
Cancer Research Fund and the American Institute for cancer research have examined the effect 
of nutrition on cancer incidence in a large study and on a global scale. The study summarized 
that approximately 30% of the cancer cases could be reduced by changing the dietary habits. 
More consumption of fruits and vegetables and less meat and dairy products can prevent cancer 
[30]
. Over the recent years, many experiments showed that nutrients act as or on transcriptional 
factors, that modify gene expression.  
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Phytochemicals are non-nutritive components in plant based diet, which show 
anticarcinogenic and antimutagenic properties 
[31]
. Some examples of the active components of 
dietary phytochemicals, which are protective against cancer are curcumin (turmeric), resveratrol 
(red grapes), lycopene (tomato), catechins (green tea), vitamin C (citrus fruits), beta carotene 
(carrot), etc. Studies have demonstrated that these dietary agents suppress the inflammatory 
processes which lead to transformation, hyperproliferation and initiation of carcinogenesis 
[30]
.    
Vitamin E plays a key role in the prevention and inhibition of cancer 
[31][32]
. This has been 
proved by investigating on many human cancers such as colon 
[33]
, lung 
[34]
, prostate 
[35]
 and 
breast 
[36]
 cancers. Vitamin E is present in most edible oils to various extents, including those 
extracted from wheat germ oil, wheat, rice bran (0.035%), barley (0.012% or 44 mg/g oil), oats 
(0.03%), coconut (0.019%) and palm (0.044%; 0.78–1.08 mg/g oil) [37].The effective role of 
vitamin E has been also demonstrated against chemotherapy resistant cancer cells. Vitamin E has 
presented efficiency against specific subhistology types of lung cancer. It is a lipophilic 
antioxidant that consists of tocopherol (α-, β-, γ-, δ-) and tocotrienol (α-, β-, γ-, δ-) isomers [30]. 
1.3.1 Tocopherols and Tocotrienol: 
Tocopherols and tocotrienols are amphipathic molecules that are members of the vitamin 
E family 
[37]
. Tocotrienols and tocopherols are collectively known as tocochromanols. They 
make up the essential nutrient, vitamin E. They are fat soluble nutrients that function as 
antioxidants in the human body. There are four types of tocotrienols and tococpherols- α, β, γ 
and δ. All these four types differ in the number and position of the methyl groups in the polar 
bond 
[37]
. 
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                         Alpha tocotrienol                                                                  Beta tocotrienol 
 
         
                         Gamma tocotrienol                                                                Delta tocotrienol 
 
Figure 1: Types of tocotrienols: Bharat B. Aggarwal, Chitra Sundaram, Seema Prasad, et al. Tocotrienols, the 
vitamin E of the 21st century: Its potential against cancer and other chronic diseases Biochemical Pharmacology 80 
(2010) 1613–1631. 
                         
                                        Alpha tocopherol                                                                    Beta tocopherol 
                        
                                       Gamma tocopherol                                                                        Delta tocopherol 
Figure 2: Types of Tocopherols: Bharat B. Aggarwal, Chitra Sundaram, Seema Prasad, et al. Tocotrienols, the vitamin E of 
the 21st century: Its potential against cancer and other chronic diseases Biochemical Pharmacology 80 (2010) 1613–1631. 
 
The tocopherols are saturated forms of vitamin E, whereas the tocotrienols are 
unsaturated and possess an isoprenoid side chain 
[37]
. Some evidence suggests that human tissues 
can convert tocotrienols to tocopherols 
[38][39]
. Numerous in vitro studies show that tocotrienols 
and tocopherols manifest anticancer, cardioprotective, and neuroprotective effects. Tocotrienols 
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suppress proliferation and induce apoptosis in wide variety of tumor cells including lung 
[40][41][42]
, breast, colon, liver, stomach, skin, pancreas
[43]
, and prostate. It has been shown that 
they can induce apoptosis by inhibiting multiple signaling pathways.  
1.3.2 Tocotrienols and Lung Cancer: 
Various studies specify that tocotrienols exhibit antioxidant, antiproliferative, 
antisurvival, proapoptotic, antiangiogenic, and anti-inflammatory activities. The antiproliferative 
activity of tocotrienols is arbitrated through modulation of growth factors such as vascular 
endothelial growth factor (VEGF) 
[44]
, basic fibroblast growth factor (bFGF) 
[45]
 and 
transforming growth factor-beta (TGF-b) 
[46]
, HER2/neu 
[47]
, and interleukin-6 (IL-6) 
[48]
. 
Tocotrienols hinder the survival of various tumor cells by inhibiting the expression of cell 
survival proteins like XIAP, IAP-1, IAP-2, bcl-2, bcl-xl, c-FLIP, TRAF-1, survivin and Bfl-
1/A1
[49]
.  
Various studies have shown that tocotrienols can induce apoptosis in a wide variety of 
tumor cells, through activation of both extrinsic and intrinsic pathways. The extrinsic pathways 
involve induction of death receptors 
[50]
 and activation of caspase-8, which leads to caspase-3 
activation 
[51]
. The intrinsic pathways involve mitochondrial depolarization 
[52]
, upregulation of 
Bax 
[53]
, cleavage of Bid 
[54]
, release of cytochrome C 
[55]
, and activation of caspase-9, which 
again leads to activation of caspase-3 
[56]
. 
The suppression of angiogenesis by tocotrienols is arbitrated through inhibition of VEGF 
expression 
[57]
 and VEGF receptor signaling 
[58]
. Suppression of the matrix metalloproteinase 
(MMP)-9 gene could also lead to the angiogenesis-suppressive activity 
[59]
. 
The results of various experiments indicate that gamma and delta tocotrienol exhibit 
greater anticancer activity than alpha or beta tocotrienol
[60]. The ﬁrst detail on the therapeutic 
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potential of tocotrienols for cancer in animal models was by Kato et al., who showed that tumor-
bearing rats administered with tocotrienols had an extended life span 
[61]
. The antitumor effects 
of tocotrienols appear through their ability to suppress angiogenesis 
[62]
. Many studies suggest 
that tocotrienols have potential to both prevent and treat cancer 
[63]
. 
 
 
Figure 3: Molecular targets of tocotrienols: B.B. Aggarwal et al. / Biochemical Pharmacology 80 (2010) 
1613–1631 
1.4 MMP9 and uPA: 
Matrix metallopeptidase 9 (MMP-9), is a matrixin, a class of enzymes that belong to 
the zinc-metalloproteinases family 
[64]
. Matrix metalloproteinase-9 (MMP-9) has been shown to 
be involved in degradation of the extracellular matrix and promotion of tumor growth and 
metastasis by its angiogenic properties 
[65]
. MMP-9 expression increases with tumor size and its 
expression is significantly higher in NSCLC cases with metastasis compared to those without 
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metastasis 
[66]
. In addition, MMP-9 expression is significantly higher in lymph node metastasis 
than primary lesions. MMP-9 has a metastasis-promoting role 
[67]
. Many studies have shown that 
MMP family contributes to tumor invasion, metastasis, and angiogenesis 
[68]
. MMP-9 
(gelatinase-B) is responsible for cell migration, aggregation, adhesion and invasion in cancer 
[69][70]
.  In order to be capable of this it degrades type IV collagen, the main component of 
extracellular matrix 
[71]
. The urokinase-type plasminogen activator (uPA) pathway and Notch-1 
pathways are major pathways that affect the MMP-9 activities in cancer.  uPA is a serine 
protease which converts inactive plasminogen to active plasmin. The active plasmin is 
responsible for the activation of MMP-9 which degrades ECM allowing the cell invasion. uPA 
also cleaves components of the ECM. It is also found to be involved in cell adhesion and 
migration. uPA receptor (uPAR) is also involved in the pathway responsible for the degradation 
of extracellular matrix 
[72]
. The uPAR is also entailed in the regulation of cell adhesion and 
migration 
[73]
. Together, MMP-9 and uPA play an important role in tumor invasion and 
metastasis.  
Plasminogen 
                  uPAR          activated uPA 
             Plasmin 
             Cleavage of proMMP-9 
         MMP-9 activation   
           Degradation of the ECM  
Fig 4: Pathway for activation of MMP-9 and degradation of ECM 
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Hypothesis: Delta tocotrienol shows anti-metastatic properties in MMP-9 mediated mechanisms 
in lung cancer.  
Specific aim I: To investigate anti-metastatic properties of delta-tocotrienol on MMP-9 on 
invitro models of NSCLC. 
Specific aim II: To investigate the underlying mechanism of the metastatic properties of MMP-9 
and uPA in NSCLC. 
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Chapter 2 
METHODOLOGY 
2.1 Cell Culture and Reagents:  
NSCLC cell lines of human A549, H1299 were obtained from ATCC. They were grown 
in RPMI medium (Mediatech, Manassas, VA) which was supplemented with 10% fetal bovine 
serum and 1% penicillin streptomycin. 5% CO2 at 37
o
C was supplied as growth parameters. Pure 
δ-tocotrienol was a kind gift from American River Nutrition (DeltaGold® MA, USA). We have 
treated the cell lines with different concentrations of pure δ-tocotrienol.   
2.2 Treatment Media and Basic Protocol: 
The treatment media is made by mixing δ-tocotrienol in RPMI medium whereas the 
control was treated with RPMI media alone. The different concentrations of δ-T used in this 
study are 10μM, 20μM and 30μM. The percentage of the RPMI media and δ-T depends on the 
no. of plates to be treated. The basic protocol followed is the confluent cells are first divided into 
petri dishes and allowed to grow for 24hrs. The optimal growth conditions in the incubator are 
5% CO2 and 37
o
C. The cells are now treated with desired concentration of δ-T of 10μM, 20μM 
and 30μM. One of the plates is maintained as control treated only with media. The cells are 
incubated for 72
 
hrs at the optimal growth conditions. The cell lysate and the media if required 
are extracted and stored for further experiments.  
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Fig 5: Basic protocol followed 
2.3 Cell Aggregation Assay: 
A single cell suspension was obtained using standard trypsinization procedure. A total of 
2 x 10 
5
 cells in 1 ml of RPMI medium with or without different concentrations of δ-T (as the 
positive control) were placed in polystyrene micro tubes and were gently shaken for every 5 min 
for 1 hr at 37
0
C.  At the end glutaraldehyde (at a final concentration 2% (v/v)) was added to stop 
the aggregation process. Homotypic aggregation was evaluated by Luna automated cell counter 
(Logos Biosystems, USA). Aggregates were counted per square cm. Significant differences 
between control and treatments were evaluated using ezANOVA. 
 
 
Confluent cells were divided into 
petridishes 
Incubated for 24 hrs to grow 
Treated with Delta-Tocotrienol of 10uM, 
20uM, 30uM concentrations 
Incubated for 72 hrs  
Cell lysate and media are extracted as 
required and stored. 
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2.4 Cell Adhesion Assay: 
The cell lines were pre-treated with or without different concentrations of δ-T (control, 
10μM, 20μM and 30μM) for 72 hrs. The cell lines were suspended in RPMI medium to form a 
single-cell suspension and 2 x 10
6
 cells/ml (2 x 10
5
 cells/well) were seeded into 96-well 
microtiter cell culture plate pre-coated with Matrigel®. After a 45 min of incubation at 37
0
C, the 
wells were washed three times with PBS to remove non-adherent cells and 10μM MTS was 
added into each well for an additional 2h. As a measure of cell viability, the absorbance at 570 
nm was taken on ELx800 plate reader (Bio-Tek, Winooski, VT). Significant differences between 
control and treatments were evaluated using ezANOVA. 
2.5 Cell Invasive Assay: 
To test the invasive ability of cells BD Biocoat invasion kit (BD, San Jose, CA) was 
used. Around 2.5 × 105 cells of A549 and H1299 with basal media were seeded in each well of 
upper chamber. This contains both untreated and treated with δ-tocotrienol (control, 10μM, 
20μM and 30μM). 3 ml of culture medium with 10% FBS was added in the mean time to the 
wells in the lower chamber of the six-well plate. The incubation time allowed was 24h. After 
incubation the cells on the upper chamber were removed with a cotton stick. The cells from the 
lower chamber were fixed in 4% Paraformaldehyde and stained with 2% crystal violet and the 
cells unbound to crystal violet were washed with PBS, before they dried. After that the stained 
crystal violet (cell bound) was washed with 20 % acetic acids. The results were evaluated 
microscopically. Also the absorbance of the dissolved crystal violet was measured at 405nm with 
ELx800 plate reader (Bio-Tek, Winooski, VT). The experimental condition was performed in 
Triplicates. 
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2.6 Wound Healing Assay: 
A million cells of NSCLC cell lines A549 and H1299 were seeded per well in a six well 
plate. The cells were incubated overnight and the culture media was removed. A scratch wound 
was made across each well using pipette tips. The wound area was washed by PBS for three 
times to remove any loosely held cells. Subsequently, the cells were cultured with or without 
treatment by δ-tocotrienol and the wound images were taken at 0 h and 20 h as pictures under 
microscope. Two diagonal parallel lines in each image mark the progress of cells that migrated 
into the wound. 
2.7 Zymogram Gel Assay: 
Zymogram gel assay was performed to detect the activity of MMP-9. A549 and H1299 
cells were seeded in a six-well plate with or without treatment by δ-tocotrienol. The media of all 
groups was removed and concentrated by 3KDa Amicon centrifugal filters (EMD Millipore, 
USA). Zymogram precast gel (Bio-Rad, Hercules, CA) with gelatin was used depending upon 
the type of the assay. One part sample was mixed with two parts of Zymogram Sample Buffer. 
Samples were loaded in the gel and the gel was run with 1x Tris-Glycine SDS Running Buffer 
according to the standard running conditions (100V, constant voltage). Run time was for 90 min 
or when the bromophenol blue tracking dye reached the bottom of the gel. After running, the 
Zymogram Renaturing Buffer (10x) was diluted (1:9) with double distilled water and the gel was 
incubated in the buffer (100 ml for one or two mini-gels) with gentle agitation for 30 minutes at 
room temperature. Later Zymogram Renaturing Buffer was decanted and replaced with 1x 
Zymogram Developing Buffer (100 ml for one or two mini-gels). The gel was equilibrated for 30 
minutes at room temperature with gentle agitation and then the buffer was replaced with fresh 1x 
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Zymogram Developing Buffer and again incubated at 37
o
C overnight for maximum sensitivity.  
The gel was stained with Coomassie Blue R-250 for 30 minutes to 1 hour the other day. For 
maximum contrast, stain concentration of 0.5% (w/v in 40% methanol and 10 % acetic acid) was 
used instead of the usual concentration of 0.1%. Gels were destained with an appropriate 
Coomassie R-250 destaining solution (161-0438) (Methanol: Acetic acid: Water (40: 10: 50). 
Areas of protease activity appeared as clear bands against a dark blue background where the 
protease has digested the substrate when measured by chemiluminescent image with chemiDoc 
XRS (Bio-Rad Laboratories, CA). 
2.8 Real-Time Quantitative PCR for Gene Expression Analysis: 
One million A549 and H1299 cells were seeded in 100mm dish per plate and incubated 
for 24 hours. Subsequently, culturing media was replaced with treatment (10μM, 20μM and 
30μM) or control medium, incubated for another 72 h. Then, Total RNA was isolated using 
RNeasy Mini Kit from QIAGEN (Valencia, CA) according to the manufacturer’s protocols. 
1000ng of total RNA from each sample was subjected to first strand cDNA synthesis using High 
capacity RNA to cDNA master mix (Applied Biosystems, Foster City, CA) in a total volume of 
50 ml. qRT-PCR was performed as part of gene expression analysis. Diluted cDNA (2 uL) and 2 
uL of each reverse and forward primer and 12.5 uL master mix (SYBR GREEN PCR Master 
Mix; Applied Biosystems, Warrington, UK) were used in each 25 uL PCR reaction performed in 
Eppendorf mastercycler realplex 4 (Eppendorf, Hauppauge, NY) at 25C for 10 min, followed by 
48 C
0
 for 30 min and 95 C
0
 for 5 min.. Expression values were normalized with β-actin.  Each 
gene expression was tested in triplicate. 
 
 
28 
 
 
                                  Forward Primer                                                     Reverse Primer 
MMP-9     5′-CGG AGT GAG TTG AAC CAG-3′           5′-GTC CCA GTG GGG ATT TAC-3′ 
2.9 Western Blot for Protein Expression Analysis: 
Western blot analysis was performed as part of protein expression analysis with 
following antibodies β-actin, MMP-9, HES-1 (Cell Signaling Technology ,Danvers, MA), uPA 
(Santa Cruz Biotechnology, USA) and Notch 1 (Life Technologies, USA ) in  cell signaling 
pathways. One million A549 and H1299 cells were seeded in 100mm dish per plate and 
incubated for 24hours, and then they were treated for 72 hours with treatment and control 
medium, incubated for 72 h. subsequently cells. Cells were lysed in the cold 1X cell lysis buffer 
(Cell Signaling Technology Danvers, MA)   for 30 min on ice with 1X Protease inhibitor (Cell 
Signaling Technology Danvers, MA). Then Protein concentrations were calculated by  using 
Pierce BSA Protein Assay  kit (Bio-Rad Laboratories, CA).Subsequently  50 mg of total cell 
lysates was  mixed with equal amount of  4X lemma buffer (Bio-Rad Laboratories, CA) and  
samples were loaded on 10% SDS-polyacrylamide gel electrophoresis. After electrophoresis, the 
gel electrophoretically was transferred to a nitrocellulose membrane (Whatman, Clifton, NJ) 
using transfer buffer (25mM Tris, 190mM glycine, 20% methanol) in Hoefer TE70XP transfer 
apparatus (Holliston, MA). The membranes were incubated for 2 h at room temperature with 5% 
nonfat dried milk in 1x TBS buffer containing 0.1% Tween 20(Fisher Scientific, USA).  After 
that, membranes were incubated over night at 4C with primary antibodies (1:1,000). The 
membranes were washed three times with TBS-T, and subsequently incubated with the 
secondary antibodies (1:5,000) containing 2% BSA for 2 h at room temperature. The signal 
intensity was then measured by chemiluminescent image with chemiDoc XRS (Bio-Rad 
Laboratories, CA). 
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2.10 Data Analysis: 
Statistically significant differences if any between groups were analyzed   using ezAnova. 
Values <0.05 were considered statistically significant.  
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Chapter 3 
RESULTS 
3.1 Cell Aggregation Assay: 
In order to test the effects of delta-tocotrienol on cell aggregation, A549 and H1299 cells 
were treated with concentrations 10µM, 20µM, 30µM of δ-tocotrienol and control. The cell lines 
were evaluated microscopically. As shown in the figures (6, 7 and 8) δ-tocotrienol inhibits cell 
aggregation in a dose dependent manner in both A549 and H1299 cells, respectively.  
                                    
                                       
                                                    
                                                             
Fig 6:  Microscopical evaluation (10X) of cell aggregation assay in A549 cell line. The results show inhibition of 
cell aggregation by δ-tocotrienol. 
31 
 
 
                           
                                                                    
                           
                                                                 
Fig 7: Microscopical evaluation (10X) of cell aggregation assay in H1299 cell lines. The results show inhibition of 
cell aggregation by δ- tocotrienol. 
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Fig 8: Effect of δ-tocotrienol on cell aggregation of A549 and H1299: Dose dependent reduction in no of cell 
aggregates in cell lines A549 (A) and H1299 (B). Vertical bars indicate the mean of cell count. All values are 
significantly different (p< 0.05). 
 
 
 
 
 
 
 
 
 
 
                   A                                                        B 
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3.2 Adhesion Assay: 
To test the effects of delta-tocotrienol on cell adhesion, A549 and H1299 cells were 
treated with increasing concentration of delta-tocotrienol for 72 h separately followed by 
adhesion assay.  MTT reagent was added and the absorbance at 570/630 was taken. The figure 
(9) shows the absorbance measured the spectrometer. From the results it can be seen that δ-
tocotrienol inhibits cell adhesion in a dose dependent manner in both A549 and H1299 cells. 
 
              
Fig 9: Effect of δ-tocotrienol on cell adhesion of A549 and H1299: Dose dependent reduction in cell adhesion in 
cell lines A549 (A) and H1299 (B). Vertical bars indicate the standard deviation. Absorption is recorded at 570/630 
nm.  All values are significantly different (p< 0.05).  
3.3 Cell Invasion Assay: 
Cell invasion assay is used to test the ability of cancer cells to penetrate through extra 
cellular matrix. MMP-9 is an important factor for cell migration and invasion. In order to 
examine the effect of δ-tocotrienol on the invasive capacity of A549 and H1299 cell lines, 
Matrigel invasion assay was conducted. Control was tested against treatment of 30μM 
concentrations. As shown in figures (10 and 11), delta-tocotrienol showed dose dependent 
decrease in the invasive capability of A549 and H1299 thus, confirming inhibition of MMP-9. 
Microscopical images and absorbance at 405nm are shown. 
B A 
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Fig 10: Microscopical evaluation (10X) of invasive ability in both cell lines A549 (A) and H1299 (B). Control is 
tested against treatment with 30μM of δ-tocotrienol. 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
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Fig 11:  Effect of δ-tocotrienol on cell invasion of A549 and H1299: A dose dependent decrease in invasive ability 
of A549 (A) and H1299 (B) cell lines with pure δ-tocotrienol. Absorption is shown against concentrations of 
treatment. Vertical bars indicate standard deviation. All values are significantly different (p<0.05).   
3.4 Wound Healing Assay: 
Wound healing assay was performed to determine tumor cell migration ability. A scratch was 
made with a pipette tip and the results were observed after 18h to evaluate the effect of δ-
tocotrienol on the migration ability of A549 and H1299 cell lines. As shown in figures (12, 13), 
δ-tocotrienol showed dose dependent inhibition in cell migration in both cell lines, A549 and 
H1299. The images were captured at time point 0 and after 20 h. 
                   A                                                        B 
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Fig 12: Microscopical evaluation (10X) of cell migration in A549 cell line. δ-tocotrienol shows inhibition in cell 
migration in treatment 30µM. 
Fig 13: Microscopical evaluation (10X) of cell migration in H1299 cell line. δ-tocotrienol shows inhibition in cell 
migration in treatment 30µM. 
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3.5 Zymogram Gel Assay: 
Zymogram gel assay is used to detect the activity of metalloproteinases. They have the 
ability to utilize gelatin as substrate. Polyacrylamide gel-based electrophoresis was used to run 
the samples of control and treatments 10μM, 20μM and 30μM. TNF- α was used as a positive 
control. A dose dependent reduction in the activity of MMP-9 by δ-tocotrienol is seen as shown 
in the figure (14).  
 
 
Fig 14: Effect of δ-tocotrienol on the effect of MMP-9: A dose dependent decrease in the activity of MMP-9 by δ-
tocotrienol treatment compared to control TNFα as positive control. 
 
 
 
 
 
 
 
 
TNFα         A0         A10         A20       A30       TNFα         H0         H10        H20       H30 
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3.6 Real-Time Quantitative PCR for Gene Expression Analysis: 
To test the effect of δ-tocotrienol on MMP-9 at gene level, Real-Time PCR was 
performed to measure the m-RNA expression of MMP-9 in both A549 and H1299 cell lines. 
Control was tested against the treatments 10μM, 20μM and 30μM. A dose dependent reduction 
in the MMP-9 gene expression was observed as shown in figure (15). 
 
 
  
Fig 15: Relative gene expression of MMP-9 in both A549 (A) and H1299 (B) cell lines. The results are dose 
dependent. 
 
 
 
 
 
                   A                                                        B 
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3.7 Western Blot for Protein Expression Analysis: 
Western Blot analysis is performed to test the effect of δ-tocotrienol on the protein 
expression level of MMP-9. Notch-1, HES-1 and uPA are also tested with different 
concentrations of treatment to evaluate the protein expression level of MMP-9. A dose dependent 
decrease is observed in the protein expression as shown in figure (16).   
 
 
                                       
                                        
                                        
                                    
        
Fig 16:  Effect of δ-tocotrienol on A549 and H1299: Down regulation of protein expressions in MMP-9 pathway 
with δ-tocotrienol. The decrease in protein expressions is dose dependent 
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Chapter 4 
DISCUSSION 
The leading cause of cancer deaths in the United States is lung cancer, and the most 
common type of cancer diagnosed in men.  Non small cell lung cancer (NSCLC) accounts for 
about 80% of the cases with less than 15% of patients surviving beyond 5 years. Despite many 
improvements in the therapeutic regimes, local recurrence of lung cancer remains to be a 
relentless problem. Thus, it is necessary to develop more effective approaches for the treatment 
of NSCLC.  
It has been found out that nutrients act as or on transcriptional factors, that modify gene 
expression for treating lung cancer. Vitamin E plays a key role in the prevention and inhibition 
of cancer. This has been proved by investigating on many human cancers such as colon, lung, 
prostate and breast cancers. Vitamin E is made up of tocopherols and tocotrienols. They are 
amphipathic molecules that are collectively known as tocochromanols. They are fat soluble 
nutrients that function as antioxidants in the human body. There are four types of tocotrienols 
and tocopherols- α, β, γ and δ. All these four types differ in the number and position of the 
methyl groups in the polar bond. This study focuses on the effect of δ-tocotrienol on the 
expression of MMP-9 in NSCLC. A549 and H1299 are two cell lines of NSCLC 
adenocarcinoma in which the effects were observed. 
MMP-9 is a class of enzymes that has been shown to be involved in degradation of the 
extracellular matrix and promotion of tumor growth and metastasis by its angiogenic properties. 
MMP-9 expression is up regulated in NSCLC cases especially those with metastasis. It is a 
gelatinase that destroys the basement membrane which is the first barrier to tumor metastasis. 
Hence elevated expression levels of MMP-9 plays an important role in tumor cell invasion and 
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metastasis.  It is responsible for metastasis by increasing cell migration, aggregation, adhesion 
and invasion in cancer cells. Cancer metastasis is a complicated multi-step process. It includes 
migration of cells, aggregation of cells, cell-cell adhesions; cell-matrix interactions, invasion into 
surrounding tissues. Our previous studies have proved that δ-tocotrienol inhibits cell growth, 
proliferation and induce apoptosis by inhibiting NF-κB via down regulating Notch-1 in dose and 
time dependent manner
[74][75]
.  This study aims at investigating the effect of δ-tocotrienol on the 
down regulation of MMP-9 and determining the underlying molecular mechanism involved. 
Anti-metastatic functions of δ-tocotrienol are assessed on cell aggregation, adhesion, invasion, 
migration, enzyme activity, gene expression and protein expression.  
Tumor cells tend to form aggregates. Aggregates exhibit lower levels of apoptosis than 
single cells. Cell aggregation facilitates metastasis in cancer and promotes higher rate of survival 
relative to existence as single cells. Another key step in metastasis is the attachment of cancer 
cells to extracellular matrix. Adhesive interactions between tumor cells and extracellular matrix 
components, and formation of aggregates play a critical role in cancer invasiveness or metastasis. 
It can be said that cell aggregation and cell adhesion are the basic or initial steps in cancer 
metastasis. We have assessed the inhibitory affects of δ-tocotrienol on cell aggregation and 
adhesion properties of MMP-9 in A549 and H1299 cell lines. Firstly, we observed a dose 
dependent decrease in cell aggregation in both cell lines for treatments 10µM, 20µM and 30µM 
when cells were plated as single cell suspension and treated with δ-tocotrienol. Equal amount of 
cells were used for each treatment. Microscopical examination was supported by the count of 
cell aggregates. All values were significantly different (p<0.05).  Next, Matrigel®-mediated 
attachment by both cell lines was inhibited by δ-tocotrienol. Equal amount of cells were seeded 
in 96 well plate coated with Matrigel®, as single cell suspension. Absorbance values were 
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recorded for treatments 10µM, 20µM and 30µM after incubation. All values were significantly 
different (p<0.05). Inhibition in cell aggregation and cell adhesion by δ-tocotrienol suggests the 
inhibition of MMP-9.  
Cell invasion is the ability of cells to navigate through the extracellular matrix within a 
tissue or infiltrate neighboring tissues by degrading the membrane barrier. The ability of the 
cancer cells to invade and metastasize to other parts of the body causes hurdles to therapeutic 
intervention. The over expression of MMP-9 in NSCLC promotes invasion. BD Biocoat matrigel 
invasion chamber was used to evaluate the effect of δ-tocotrienol on the invasive ability of 
MMP-9. The kit contains matrigel basement membrane matrix which serves as a reconstituted 
basement membrane in vitro. Upper chamber is seeded with equal amount of cells for control 
and desired concentration of treatments and the lower chamber is filled with media to support the 
invading cells. The matrigel layer clogs the pores of the membrane, blocking the non-invasive 
cells from migrating through the membrane. In contrast, cells with the capability to invade and 
detach themselves from the upper chamber pass through the matrigel matrix to reach the lower 
chamber. The incubation time allowed in the study is 24h. The non-invasive cells on the upper 
chamber are removed with a cotton swab.  
A dose dependent decrease in the invasive ability was observed, when control was 
examined over treatment with 30μM of δ-tocotrienol microscopically and when the absorbance 
was plotted against control and treatments 10μM, 20μM, 30μM. Cell invasion assay shows 
inhibition in MMP-9 expression with δ-tocotrienol treatment. 
Cell migration, the movement of cells from one area to another is achieved in wound 
healing, cell differentiation, embryonic development and metastasis of tumors. Cancer 
combativeness is affected to a great extent by its invasive capability for which cell migration is a 
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determinant manifestation. Wound healing assay is a convenient method to assess cell migration 
in vitro. This method basically comprises of creating a scratch on a monolayer cells and observe 
the changes after a time point. Due to the migration ability of cells increased as a result of over 
expression of MMP-9, the wound (scratch) closes with the movement of cells across the scratch. 
This method mimics to some extent migration of cells in vivo. The results were captured by a 
microscope to discern the migration at time point 0 with migration after 18h. A dose dependent 
decrease in the migration ability of cells was observed when control was assessed against 
treatment thus, confirming inhibition of MMP-9 by δ-tocotrienol. The absorbance values 
recorded for treatments 10µM, 20µM and 30µM also support this will all the values being 
significantly different (p<0.05). All the above results lead to the conclusion that δ-tocotrienol 
effectively inhibits several steps which are involved in cell metastasis like aggregation, adhesion, 
invasion and migration. 
MMP-9 has the ability to degrade gelatin, major component of basement membrane. It 
uses gelatin as substrate. So the activity of this enzyme can be interpreted by the amount of 
gelatin utilized by the enzyme. Zymogram gel assay is employed for this purpose. This assay 
applies a sensitive quantifiable polyacrylamide gel-based electrophoretic approach that 
associates the ability of the proteases with degrading the substrate, gelatin. Clear bands against a 
dark background are observed as a result, which shows the digested substrate by the proteases. 
Cell media was used to analyze the MMP-9 activity. The RPMI media used to incubate the cells 
was not supplemented with FBS as itself contains MMP-9 that could interfere with the 
Zymogram gel assay.    
Tumor necrosis factor alpha (TNFα) is used as positive control. TNFα is a member of 
TNF cytokine family and is a cell signaling protein that is involved in systemic inflammation. 
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One of the pivotal chemical mediators embroiled in inflammation related cancers is TNF-α. It is 
involved in promotion and progression of cancer through activating transcriptional factors like 
NF-κB. The samples used for performing Zymogram gel assay included those added with TNFα, 
control and treatments 10μM, 20μM, 30μM. A dose dependent decrease in the band size was 
observed with δ-tocotrienol which confirms the inhibition in MMP-9 activity. 
It has already been shown that MMP-9 over expresses in NSCLC 
[76]
. The purpose of this 
study was to examine if δ-tocotrienol down regulates MMP-9 expression in lung cancer. In order 
to understand the underlying mechanism of anti-metastatic properties of δ-tocotrienol on MMP-
9, studying its expression at gene and protein level is important. Real-Time PCR analysis and 
Western blot analysis were performed to examine MMP-9 gene and protein expressions. 
Expression of β-actin is used as reference. The Ct count for both the cell lines was used to find 
the relative expression for each treatment. A dose dependent decrease in the relative expression 
was observed.  
Previously we showed that δ-tocotrienol down regulates Notch-1 expression. MMP-9 
follows a downstream pathway to Notch-1 and HES-1. Another pathway includes uPA upstream 
to MMP-9. In order to see effects of δ-tocotrienol on MMP-9 protein expression, its effects on 
Notch-1, HES-1 and uPA protein expressions were also studied by western blot analysis. β-actin 
was used as reference protein. A dose dependent reduction in the band size was observed for 
treatments 10μM, 20μM and 30μM with control for all the genes. This suggests that MMP-9 
expression is decreased by the δ-tocotrienol treatment. 
In summary, the study shows that δ-tocotrienol shows inhibition in metastatic properties 
of MMP-9 like cell aggregation, adhesion, invasion, migration and in activity of the enzyme in 
NSCLC cells. When molecular mechanisms were investigated, there is a decrease in the gene 
45 
 
 
expression and protein expression levels of MMP-9 by δ-tocotrienol. Further, this study supports 
the Notch-1 signaling pathway and uPA pathway. Further investigation in animal models and 
clinical trials need to be done to prove the effect of pure δ-tocotrienol on NSCLC.    
 
Fig 16: δ-tocotrienol down regulating genes in MMP-9 pathway 
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ABSTRACT 
DELTA-TOCOTRIENOL DOWN REGULATES MMP-9 EXPRESSION IN 
NSCLC CELLS 
 
by 
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Degree: Master of Science 
Lung cancer is the leading cause of cancer death in Unites States. The main types of lung 
cancer are small cell lung cancer and non small cell lung cancer. NSCLC accounts for about 80% 
of the cases with less than 15% of patients surviving beyond 5 years. Most common causes of 
lung cancer are smoking, inhaling asbestos fiber, radon gas, passive smoking, air pollution, 
familial predisposition, prior history of lung cancer etc. Surgery, chemotherapy, targeted therapy, 
palliative care are commonly used treatment techniques for lung cancer. Radiation therapy is an 
important part of lung cancer management. The objective of this study was to investigate if δ-
tocotrienol which is an isoform of essential nutrient vitamin E can be successfully used in the 
treatment of NSCLC. The effect of pure δ-tocotrienol was studied on NSCLC cell lines A549 
and H1299. Previously it was proved that Notch-1 pathway could be a therapeutic target for 
NSCLC and also that pure δ-tocotrienol down regulates Notch-1 via NF -КB. This study mainly 
focuses on MMP-9 and uPA expression in the NSCLC cell lines via Notch-1 and HES-1. 
Aggregation and adhesion capability, invasive and migration ability, MMP-9 activity and 
57 
 
 
molecular mechanisms like gene expression and protein expression were evaluated. Different 
assays like cell aggregation assay, cell adhesion assay, cell invasion assay, wound healing assay, 
zymogram gel assay, Real-Time PCR analysis, Western Blot analysis were performed for this 
purpose. A dose dependent decrease was observed in MMP-9 activity confirming its inhibition. 
Since there is inhibition in cell aggregation, adhesion, invasion, migration, gene and protein 
expressions, the study suggests that administration with pure δ-tocotrienol could be an effective 
approach for the treatment of NSCLC.  
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